Pacira BioSciences (PCRX) Total Non-Current Liabilities (2016 - 2025)
Pacira BioSciences (PCRX) has 16 years of Total Non-Current Liabilities data on record, last reported at $551.2 million in Q4 2025.
- For Q4 2025, Total Non-Current Liabilities fell 27.31% year-over-year to $551.2 million; the TTM value through Dec 2025 reached $551.2 million, down 27.31%, while the annual FY2025 figure was $551.2 million, 27.31% down from the prior year.
- Total Non-Current Liabilities reached $551.2 million in Q4 2025 per PCRX's latest filing, roughly flat from $552.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.3 billion in Q4 2021 and bottomed at $551.2 million in Q4 2025.
- Average Total Non-Current Liabilities over 5 years is $767.4 million, with a median of $743.8 million recorded in 2023.
- Peak YoY movement for Total Non-Current Liabilities: soared 100.77% in 2021, then crashed 33.91% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at $1.3 billion in 2021, then tumbled by 30.36% to $896.5 million in 2022, then fell by 24.2% to $679.6 million in 2023, then rose by 11.59% to $758.4 million in 2024, then decreased by 27.31% to $551.2 million in 2025.
- Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $551.2 million in Q4 2025, $552.5 million in Q3 2025, and $762.3 million in Q2 2025.